| NCT03268213 |
Fecal Microbial Transplantation for C. Difficile and/or Ulcerative Colitis or Indeterminate Colitis |
https://ClinicalTrials.gov/show/NCT03268213 |
Active, not recruiting |
Stony Brook University |
2022-06-30 |
| NCT02531126 |
Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02531126 |
Active, not recruiting |
Celgene |
2022-02-28 |
| NCT04277546 |
Open-label Extension Study of Brazikumab in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT04277546 |
Enrolling by invitation |
Allergan |
2023-04-12 |
| NCT02365480 |
Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission |
https://ClinicalTrials.gov/show/NCT02365480 |
Active, not recruiting |
National Cancer Institute (NCI) |
2018-02-16 |
| NCT03138655 |
Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn’s Disease (CD) |
https://ClinicalTrials.gov/show/NCT03138655 |
Completed |
Takeda |
2020-03-31 |
| NCT04090411 |
A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adult Participants With Moderate to Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT04090411 |
Recruiting |
Pfizer |
2023-10-24 |
| NCT04033445 |
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT04033445 |
Recruiting |
Janssen Research & Development, LLC |
2022-06-29 |
| NCT04004611 |
A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC) |
https://ClinicalTrials.gov/show/NCT04004611 |
Recruiting |
Eli Lilly and Company |
2022-07-21 |
| NCT03950232 |
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03950232 |
Recruiting |
Arena Pharmaceuticals |
2024-10-31 |
| NCT03662542 |
A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03662542 |
Recruiting |
Janssen Research & Development, LLC |
2020-11-17 |
| NCT03648541 |
BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03648541 |
Recruiting |
Boehringer Ingelheim |
2031-03-30 |
| NCT03596645 |
A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03596645 |
Recruiting |
Janssen Research & Development, LLC |
2021-12-22 |
| NCT03524092 |
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03524092 |
Recruiting |
Eli Lilly and Company |
2021-03-16 |
| NCT03519945 |
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) |
https://ClinicalTrials.gov/show/NCT03519945 |
Recruiting |
Eli Lilly and Company |
2023-08-23 |
| NCT03518086 |
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1) |
https://ClinicalTrials.gov/show/NCT03518086 |
Recruiting |
Eli Lilly and Company |
2020-09-07 |
| NCT03378167 |
PediCRaFT: Pediatric Crohn’s Disease Fecal Transplant Trial |
https://ClinicalTrials.gov/show/NCT03378167 |
Recruiting |
McMaster Children’s Hospital |
2021-07-31 |
| NCT02822352 |
RCT: HDWL vs Virtual Chromoendoscopy in the Detection of Intraepithelial Neoplasia in Longstanding Colitis |
https://ClinicalTrials.gov/show/NCT02822352 |
Completed |
Portsmouth Hospitals NHS Trust |
2018-03-08 |
| NCT00336492 |
A Study of the Safety and Efficacy of Infliximab(REMICADE ) in Pediatric Patients With Moderately to SeverelyActive Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00336492 |
Completed |
Centocor, Inc. |
2009-05-31 |
| NCT04176588 |
A Phase 3 Study of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT04176588 |
Recruiting |
Everstar Therapeutics Limited |
2022-10-31 |
| NCT03937609 |
TITRATE (inducTIon for acuTe ulceRATivE Colitis) |
https://ClinicalTrials.gov/show/NCT03937609 |
Recruiting |
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
2023-12-31 |
| NCT02606032 |
Trial of Antimicrobials Versus Placebo in Addition to Fecal Transplant Therapy in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02606032 |
Recruiting |
Hamilton Health Sciences Corporation |
2019-12-31 |
| NCT03945188 |
Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03945188 |
Recruiting |
Arena Pharmaceuticals |
2021-11-30 |
| NCT03482635 |
BI655130 (SPESOLIMAB) Induction Treatment in Patients With Moderate-to-severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03482635 |
Completed |
Boehringer Ingelheim |
2020-05-18 |
| NCT03462459 |
Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT03462459 |
Recruiting |
University of Wisconsin, Madison |
2021-12-31 |
| NCT01045018 |
A BE Study Comparing Mesalamine 400 mg to ASACOL® 400 mg in Patients With Mild To Moderately Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01045018 |
Completed |
EMET Pharmaceuticals, LLC |
2009-06-30 |
| NCT01036022 |
Effect of GSK1399686 in Patients With Mild to Moderately Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01036022 |
Completed |
GlaxoSmithKline |
2013-01-10 |
| NCT00889161 |
Curcumin in Pediatric Inflammatory Bowel Disease |
https://ClinicalTrials.gov/show/NCT00889161 |
Completed |
Seattle Children’s Hospital |
2010-06-30 |
| NCT01465763 |
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01465763 |
Completed |
Pfizer |
2015-05-31 |
| NCT03341962 |
Phase 2 Dose-finding IMU-838 for Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03341962 |
Recruiting |
Immunic AG |
2022-07-10 |
| NCT03301311 |
Personalized Research on Diet in Ulcerative Colitis and Crohn’s Disease |
https://ClinicalTrials.gov/show/NCT03301311 |
Active, not recruiting |
Children’s Hospital Medical Center, Cincinnati |
2020-12-02 |
| NCT03290781 |
An Efficacy and Safety Study of Ontamalimab as Maintenance Therapy in Participants With Moderate to Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03290781 |
Recruiting |
Shire |
2024-06-15 |
| NCT03298022 |
Efficacy and Safety of AbGn-168H in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03298022 |
Recruiting |
AbGenomics International, Inc. |
2020-04-30 |
| NCT03281304 |
A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission |
https://ClinicalTrials.gov/show/NCT03281304 |
Active, not recruiting |
Pfizer |
2020-02-14 |
| NCT03283085 |
A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn’s Disease (AIDA) |
https://ClinicalTrials.gov/show/NCT03283085 |
Recruiting |
Shire |
2025-02-11 |
| NCT03275467 |
Faecal Microbiota Transplantation in Patients With Microscopic Colitis |
https://ClinicalTrials.gov/show/NCT03275467 |
Completed |
Örebro University, Sweden |
2019-06-05 |
| NCT03269695 |
Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission. |
https://ClinicalTrials.gov/show/NCT03269695 |
Recruiting |
Pfizer |
2021-07-27 |
| NCT02463305 |
Therapeutic Modulation of the Intestinal Creatine Kinase System in Inflammatory Bowel Disease (IBD) |
https://ClinicalTrials.gov/show/NCT02463305 |
Recruiting |
University of Colorado, Denver |
2020-12-31 |
| NCT03221036 |
Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03221036 |
Recruiting |
Takeda |
2022-05-16 |
| NCT03209232 |
Infliximab Accelerated Induction in Moderate to Severe Pediatric UC |
https://ClinicalTrials.gov/show/NCT03209232 |
Recruiting |
Schneider Children’s Medical Center, Israel |
2021-12-31 |
| NCT03196427 |
Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn’s Disease (CD) |
https://ClinicalTrials.gov/show/NCT03196427 |
Active, not recruiting |
Takeda |
2021-01-03 |
| NCT03182166 |
Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization |
https://ClinicalTrials.gov/show/NCT03182166 |
Recruiting |
Centre Hospitalier Universitaire de Saint Etienne |
2020-10-30 |
| NCT03178669 |
The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03178669 |
Active, not recruiting |
InDex Pharmaceuticals |
2019-09-30 |
| NCT03172195 |
Detection of Herpesvirus DNA (CMV, EBV, HHV-6 and HSV) in Colonic Tissue: Impact on Ulcerative Colitis Flare-up |
https://ClinicalTrials.gov/show/NCT03172195 |
Recruiting |
Centre Hospitalier Universitaire de Saint Etienne |
2021-06-30 |
| NCT03259334 |
Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03259334 |
Active, not recruiting |
Shire |
2024-07-12 |
| NCT03122613 |
Curcumin for Prevention of Relapse in Patients With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03122613 |
Recruiting |
Chinese University of Hong Kong |
2020-04-30 |
| NCT03259308 |
Efficacy and Safety Study of SHP647 as Induction Therapy in Participants With Moderate to Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03259308 |
Active, not recruiting |
Shire |
2024-07-12 |
| NCT03103412 |
TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC) |
https://ClinicalTrials.gov/show/NCT03103412 |
Completed |
Theravance Biopharma |
2017-11-08 |
| NCT03101800 |
Beneficial and Harmful Effects of Azathioprine and Allopurinol Versus Standard Azathioprine Therapy for Patients With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03101800 |
Recruiting |
Hvidovre University Hospital |
2019-11-14 |
| NCT03093259 |
ABX464 in Subjects With Moderate to Severe Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03093259 |
Completed |
Abivax S.A. |
2018-06-30 |
| NCT03091309 |
Counseling to Optimize Adherence in Expectant Mothers With Inflammatory Bowel Disease |
https://ClinicalTrials.gov/show/NCT03091309 |
Recruiting |
Mount Sinai Hospital, Canada |
2020-10-01 |
| NCT03235752 |
Safety and Efficacy of TJ301 IV in Participants With Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03235752 |
Recruiting |
I-Mab Biopharma HongKong Limited |
2020-12-26 |
| NCT03011268 |
Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not? |
https://ClinicalTrials.gov/show/NCT03011268 |
Recruiting |
Helse Møre og Romsdal HF |
2021-12-31 |
| NCT03006809 |
Optimal Fecal Microbiota Transplant Dosing for Mild to Moderate Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03006809 |
Recruiting |
University of California, San Francisco |
2020-12-31 |
| NCT03000101 |
Study of the Role of Pomegranate Juice Ellagitannins in the Modulation of Inflammation in Inflammatory Bowel Disease |
https://ClinicalTrials.gov/show/NCT03000101 |
Active, not recruiting |
Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi |
2020-07-31 |
| NCT02994836 |
GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation ) |
https://ClinicalTrials.gov/show/NCT02994836 |
Recruiting |
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa |
2021-12-31 |
| NCT02985593 |
A Phase 1 Study of KHK4083 in Healthy Volunteers and Subjects With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02985593 |
Completed |
Kyowa Kirin Co., Ltd. |
2017-12-26 |
| NCT02958865 |
Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02958865 |
Recruiting |
Pfizer |
2020-12-06 |
| NCT02163759 |
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #1) |
https://ClinicalTrials.gov/show/NCT02163759 |
Completed |
Hoffmann-La Roche |
2020-02-19 |
| NCT02922881 |
Microbiota-targeted Diet for Pediatric UC |
https://ClinicalTrials.gov/show/NCT02922881 |
Recruiting |
Children’s Hospital of Philadelphia |
2020-07-31 |
| NCT02914535 |
Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02914535 |
Active, not recruiting |
Gilead Sciences |
2023-11-30 |
| NCT02914522 |
Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02914522 |
Completed |
Gilead Sciences |
2020-03-31 |
| NCT02910245 |
Mercaptopurine Therapy in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02910245 |
Recruiting |
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
2022-04-30 |
| NCT02903966 |
GSK2982772 Study in Subjects With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02903966 |
Completed |
GlaxoSmithKline |
2019-06-17 |
| NCT02100696 |
A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors |
https://ClinicalTrials.gov/show/NCT02100696 |
Completed |
Hoffmann-La Roche |
2020-04-16 |
| NCT02888379 |
Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02888379 |
Completed |
Topivert Pharma Ltd |
2017-06-28 |
| NCT02883452 |
A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn’s Disease and Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02883452 |
Completed |
Celltrion |
2019-02-04 |
| NCT02878083 |
Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT) |
https://ClinicalTrials.gov/show/NCT02878083 |
Recruiting |
Nantes University Hospital |
2019-07-31 |
| NCT02862132 |
Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases |
https://ClinicalTrials.gov/show/NCT02862132 |
Recruiting |
Shaare Zedek Medical Center |
2020-07-31 |
| NCT02840721 |
Safety, Efficacy, and Tolerability Study of PF-06480605 in Subjects With Moderate to Severe Ulcerative Colitis. |
https://ClinicalTrials.gov/show/NCT02840721 |
Completed |
Pfizer |
2018-05-31 |
| NCT02825914 |
CAsein GLycomacropeptide in Ulcerative Colitis - Anti-Inflammatory and Microbiome Modulating Effects (CAGLUCIM) |
https://ClinicalTrials.gov/show/NCT02825914 |
Completed |
University of Aarhus |
2019-07-01 |
| NCT02818543 |
Safety and Pharmacokinetic Study of LYC-30937 in Subjects With Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02818543 |
Completed |
Lycera Corp. |
2016-06-30 |
| NCT01340872 |
Safety and Efficacy Study of Oral Ferric Iron To Treat Iron Deficiency Anaemia in Quiescent Ulcerative Colitis (AEGIS-1) |
https://ClinicalTrials.gov/show/NCT01340872 |
Completed |
Shield Therapeutics |
2013-10-31 |
| NCT02762500 |
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02762500 |
Completed |
Lycera Corp. |
2018-05-31 |
| NCT02749630 |
A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs), Participants With Ulcerative Colitis (UC), and Participants With Crohn’s Disease (CD) |
https://ClinicalTrials.gov/show/NCT02749630 |
Completed |
Genentech, Inc. |
2020-02-19 |
| NCT02748590 |
Evaluation of Sacral Neuromodulation (SNM) in the Treatment of Active Ulcerative Colitis (PRIMICISTIM) |
https://ClinicalTrials.gov/show/NCT02748590 |
Completed |
Nantes University Hospital |
2020-01-31 |
| NCT02743806 |
Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn’s Disease |
https://ClinicalTrials.gov/show/NCT02743806 |
Active, not recruiting |
Takeda |
2022-02-15 |
| NCT02734589 |
Fecal Transplantation Using a Diet for Donor and Recipient in Refractory Colitis |
https://ClinicalTrials.gov/show/NCT02734589 |
Recruiting |
Wolfson Medical Center |
2020-04-30 |
| NCT02687724 |
Golimumab (GLM) Dose Optimisation to Adequate Levels to Achieve Response in Colitis |
https://ClinicalTrials.gov/show/NCT02687724 |
Recruiting |
University College Dublin |
2020-02-29 |
| NCT02665845 |
Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone (for Ulcerative Colitis). |
https://ClinicalTrials.gov/show/NCT02665845 |
Recruiting |
Centre Hospitalier Universitaire de Saint Etienne |
2021-09-30 |
| NCT02647866 |
Study of a Monoclonal Antibody KHK4083 in Moderate Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02647866 |
Completed |
Kyowa Kirin Pharmaceutical Development, Inc. |
2018-09-30 |
| NCT02646657 |
An Open Label Phase 4 Study to Evaluate Efficacy of Early Versus Late Use of Vedolizumab in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02646657 |
Recruiting |
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
2021-12-31 |
| NCT02632175 |
Long-term Safety and Efficacy Study of Adalimumab in Pediatric Subjects With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02632175 |
Active, not recruiting |
AbbVie |
2025-03-05 |
| NCT02622139 |
Multispectral Optoacoustic Tomography (MSOT) for the Evaluation of Disease Activity in Inflammatory Bowel Diseases (IBD) |
https://ClinicalTrials.gov/show/NCT02622139 |
Completed |
University of Erlangen-Nürnberg Medical School |
2017-10-31 |
| NCT02620046 |
Vedolizumab Subcutaneous Long-Term Open-Label Extension Study |
https://ClinicalTrials.gov/show/NCT02620046 |
Active, not recruiting |
Takeda |
2021-08-11 |
| NCT02618187 |
A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02618187 |
Completed |
Seres Therapeutics, Inc. |
2017-12-06 |
| NCT02611830 |
Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02611830 |
Completed |
Takeda |
2018-05-30 |
| NCT02589665 |
A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02589665 |
Completed |
Eli Lilly and Company |
2017-12-19 |
| NCT03616821 |
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis [EXPEDITION] |
https://ClinicalTrials.gov/show/NCT03616821 |
Recruiting |
Allergan |
2020-08-30 |
| NCT03029143 |
Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03029143 |
Active, not recruiting |
Takeda |
2020-07-15 |
| NCT02819635 |
A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC) |
https://ClinicalTrials.gov/show/NCT02819635 |
Recruiting |
AbbVie |
2021-10-07 |
| NCT02569333 |
Patient Centered Algorithms to Optimize the Inpatient Experience and Treatment of Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02569333 |
Completed |
Mount Sinai Hospital, Canada |
2019-01-31 |
| NCT02559713 |
Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn’s Disease |
https://ClinicalTrials.gov/show/NCT02559713 |
Completed |
Takeda |
2019-02-22 |
| NCT03398148 |
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic Therapy |
https://ClinicalTrials.gov/show/NCT03398148 |
Recruiting |
AbbVie |
2022-03-09 |
| NCT03398135 |
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065 |
https://ClinicalTrials.gov/show/NCT03398135 |
Recruiting |
AbbVie |
2022-12-04 |
| NCT02550418 |
Budesonide 9 mg Capsules in Active UC |
https://ClinicalTrials.gov/show/NCT02550418 |
Completed |
Dr. Falk Pharma GmbH |
2017-03-31 |
| NCT02550158 |
A Study Evaluating the Impact of an Educational Program (EDU-MICI) on Patients With Inflammatory Bowel Disease |
https://ClinicalTrials.gov/show/NCT02550158 |
Completed |
Groupe d’Etude Therapeutique des Affections Inflammatoires Digestives |
2014-11-30 |
| NCT02543021 |
Virtual Chromoendoscopy for Colitis Surveillance: A Feasibility Study |
https://ClinicalTrials.gov/show/NCT02543021 |
Completed |
King’s College Hospital NHS Trust |
2017-11-01 |
| NCT02537210 |
Aminosalicylic Acid Withdrawal Study in Long Standing Inactive Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02537210 |
Recruiting |
Chinese University of Hong Kong |
2021-09-30 |
| NCT02536404 |
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02536404 |
Completed |
Arena Pharmaceuticals |
2018-11-01 |
| NCT02522780 |
Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC) |
https://ClinicalTrials.gov/show/NCT02522780 |
Completed |
Ferring Pharmaceuticals |
2018-09-19 |
| NCT02516384 |
Fecal Microbiota Transplantation (FMT) in the Management of Ulcerative Colitis (UC) |
https://ClinicalTrials.gov/show/NCT02516384 |
Completed |
Weill Medical College of Cornell University |
2016-12-31 |
| NCT03594708 |
Immunonutrition in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03594708 |
Recruiting |
Baptist Memorial Health Care Corporation |
2018-12-31 |
| NCT02497469 |
An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02497469 |
Completed |
Takeda |
2018-09-26 |
| NCT02493712 |
A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M |
https://ClinicalTrials.gov/show/NCT02493712 |
Completed |
Holy Stone Healthcare Co., Ltd |
2018-07-31 |
| NCT02487238 |
Pediatric FEcal Microbiota Transplant for Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02487238 |
Completed |
McMaster Children’s Hospital |
2018-12-31 |
| NCT02469103 |
The Utility of Second Generation Colon Capsule Endoscopy in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02469103 |
Completed |
Chinese University of Hong Kong |
2018-01-31 |
| NCT02463045 |
Study for Safety and Tolerability of TOP1288 Administered Rectally in Healthy and Ulcerative Colitis Subjects |
https://ClinicalTrials.gov/show/NCT02463045 |
Completed |
Topivert Pharma Ltd |
2016-07-31 |
| NCT02447302 |
Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02447302 |
Completed |
Arena Pharmaceuticals |
2018-02-14 |
| NCT02435992 |
Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02435992 |
Active, not recruiting |
Celgene |
2020-03-27 |
| NCT02426372 |
Safety and Efficacy of QBECO in Moderate to Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02426372 |
Completed |
Qu Biologics Inc. |
2016-12-31 |
| NCT02425865 |
Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis - In-TARGET |
https://ClinicalTrials.gov/show/NCT02425865 |
Recruiting |
Groupe d’Etude Therapeutique des Affections Inflammatoires Digestives |
2020-09-30 |
| NCT02425852 |
A Randomized, Multicenter Open Label Study Comparing Early Administration of Azathioprine Plus IFX to Steroids Plus Azathioprine for Acute Severe Colitis |
https://ClinicalTrials.gov/show/NCT02425852 |
Recruiting |
Groupe d’Etude Therapeutique des Affections Inflammatoires Digestives |
2020-12-31 |
| NCT02423460 |
Threonine Requirement in IBD Adults and Healthy Adult Controls |
https://ClinicalTrials.gov/show/NCT02423460 |
Completed |
Nestlé |
2018-09-17 |
| NCT02421705 |
Visceral Sensitivity in IBD (Irritable Bowel Disease) and IBS (Irritable Bowel Syndrome) |
https://ClinicalTrials.gov/show/NCT02421705 |
Recruiting |
KU Leuven |
2099-01-31 |
| NCT02407236 |
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02407236 |
Active, not recruiting |
Janssen Research & Development, LLC |
2018-08-10 |
| NCT02390726 |
Fecal Microbiota Transplant in the Treatment of Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02390726 |
Active, not recruiting |
University of Vermont |
2017-12-31 |
| NCT02368717 |
An Efficacy and Safety Study of PENTASA in Chinese Patients With Left-sided Active Ulcerative Colitis Followed by a 24-Week Open-Label Extension Phase |
https://ClinicalTrials.gov/show/NCT02368717 |
Completed |
Ferring Pharmaceuticals |
2017-01-05 |
| NCT02370056 |
Evaluation of 3D Visualization for Total Colectomy |
https://ClinicalTrials.gov/show/NCT02370056 |
Completed |
The Cleveland Clinic |
2019-05-17 |
| NCT02345733 |
Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02345733 |
Recruiting |
Wolfson Medical Center |
2020-12-31 |
| NCT02337608 |
Efficacy and Safety of GLPG1205 in Subjects With Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02337608 |
Completed |
Galapagos NV |
2015-09-30 |
| NCT02330653 |
Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02330653 |
Completed |
Boston Children’s Hospital |
2019-04-08 |
| NCT02322307 |
Trial on Impact of HealthPROMISE Mobile App on Inflammatory Bowel Disease Care and Quality of Life |
https://ClinicalTrials.gov/show/NCT02322307 |
Completed |
Icahn School of Medicine at Mount Sinai |
2020-01-20 |
| NCT02319798 |
Telephone Consultation as a Substitute for Routine Out-patient Face-to-face Consultation for Children With Inflammatory Bowel Disease |
https://ClinicalTrials.gov/show/NCT02319798 |
Completed |
Manchester University NHS Foundation Trust |
2013-07-31 |
| NCT02318667 |
Correlation of Soluble Suppression of Tumorigenicity 2 (ST2) With Golimumab (MK-8259) Response in Participants With Ulcerative Colitis (UC) (MK-8529-022). |
https://ClinicalTrials.gov/show/NCT02318667 |
Completed |
Merck Sharp & Dohme Corp. |
2017-06-21 |
| NCT01562314 |
A Pilot Study of GWP42003 in the Symptomatic Treatment of Ulcerative Colitis (GWID10160) |
https://ClinicalTrials.gov/show/NCT01562314 |
Completed |
GW Research Ltd |
2014-08-05 |
| NCT02303132 |
Ussing Experiments to Evaluate the Role of Medication-induced Microscopic Colitis |
https://ClinicalTrials.gov/show/NCT02303132 |
Completed |
Maastricht University Medical Center |
2016-06-30 |
| NCT02306785 |
TP0502-Pharmaco-Scintigraphic-Study and Amendment |
https://ClinicalTrials.gov/show/NCT02306785 |
Completed |
Tillotts Pharma AG |
2013-02-28 |
| NCT02289417 |
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02289417 |
Completed |
Amgen |
2017-09-25 |
| NCT02280629 |
Phosphatidylcholine (LT-02) vs. Placebo vs. Mesalamine for Maintenance of Remission in Ulcerative Colitis (PROTECT-2) |
https://ClinicalTrials.gov/show/NCT02280629 |
Completed |
Dr. Falk Pharma GmbH |
2018-10-05 |
| NCT02277223 |
Curcumin in Pediatric Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02277223 |
Recruiting |
Schneider Children’s Medical Center, Israel |
2022-07-31 |
| NCT02267694 |
Study of Freeze-dried Black Raspberry in Maintenance of Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02267694 |
Completed |
UConn Health |
2015-10-05 |
| NCT00694980 |
A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of rhuMAb Beta7 in Patients With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00694980 |
Completed |
Genentech, Inc. |
2011-09-30 |
| NCT02246361 |
Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication |
https://ClinicalTrials.gov/show/NCT02246361 |
Completed |
Floralis |
2015-05-31 |
| NCT02227342 |
Fecal Microbiota Transplantation (FMT) in the Management of Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02227342 |
Completed |
University of Alberta |
2016-12-31 |
| NCT02213835 |
Treatment With the Specific Carbohydrate Diet for Children With Active Crohns Disease and Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02213835 |
Completed |
Seattle Children’s Hospital |
2017-09-30 |
| NCT02200445 |
Low Dose IL-2 for Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02200445 |
Recruiting |
Boston Children’s Hospital |
2020-06-30 |
| NCT04074590 |
Study of Efficacy, Safety, and Tolerability of LYS006, in Patients With Mild to Moderate Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT04074590 |
Recruiting |
Novartis |
2021-12-13 |
| NCT02171429 |
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #2) |
https://ClinicalTrials.gov/show/NCT02171429 |
Completed |
Hoffmann-La Roche |
2020-03-02 |
| NCT02165215 |
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors |
https://ClinicalTrials.gov/show/NCT02165215 |
Completed |
Hoffmann-La Roche |
2020-04-06 |
| NCT02155335 |
Preference for a Prefilled Syringe or Smartjectâ„¢ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027) |
https://ClinicalTrials.gov/show/NCT02155335 |
Completed |
Merck Sharp & Dohme Corp. |
2015-10-05 |
| NCT02148640 |
The NOR-SWITCH Study |
https://ClinicalTrials.gov/show/NCT02148640 |
Completed |
Diakonhjemmet Hospital |
2016-06-30 |
| NCT02142634 |
Budesonide for Induction of Remission in Incomplete Microscopic Colitis |
https://ClinicalTrials.gov/show/NCT02142634 |
Active, not recruiting |
Dr. Falk Pharma GmbH |
2020-02-29 |
| NCT02138318 |
High Definition Versus Chromoendoscopy for Dysplasia Detection in Ulcerative Colitis (UC) |
https://ClinicalTrials.gov/show/NCT02138318 |
Completed |
The Leeds Teaching Hospitals NHS Trust |
2015-09-19 |
| NCT02136069 |
A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors |
https://ClinicalTrials.gov/show/NCT02136069 |
Active, not recruiting |
Hoffmann-La Roche |
2020-04-27 |
| NCT02129439 |
Efficacy, Pharmacokinetics, Tolerability, Safety of SB012 Intrarectally Applied in Active Ulcerative Colitis Patients |
https://ClinicalTrials.gov/show/NCT02129439 |
Completed |
Sterna Biologicals GmbH & Co. KG |
2017-06-22 |
| NCT02120391 |
Improving Knowledge of Medication in Ulcerative Colitis With an Iphone Application |
https://ClinicalTrials.gov/show/NCT02120391 |
Completed |
University of Wisconsin, Madison |
2017-06-30 |
| NCT02118584 |
Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies |
https://ClinicalTrials.gov/show/NCT02118584 |
Recruiting |
Hoffmann-La Roche |
2025-08-16 |
| NCT02108821 |
Fecal Microbiota Transplantation in Pediatric Patients |
https://ClinicalTrials.gov/show/NCT02108821 |
Completed |
Children’s Mercy Hospital Kansas City |
2017-05-30 |
| NCT02093780 |
Personalized “Alberta” Diet for Prevention of Relapse in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02093780 |
Completed |
University of Alberta |
2017-10-31 |
| NCT02093767 |
Oligofructose-enriched Inulin for the Treatment of Mild to Moderate Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02093767 |
Completed |
University of Alberta |
2010-09-30 |
| NCT02093663 |
Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02093663 |
Completed |
Shire |
2018-11-28 |
| NCT02092285 |
Golimumab Utilization and Impact on Ulcerative Colitis (MK-8259-032) |
https://ClinicalTrials.gov/show/NCT02092285 |
Completed |
Merck Sharp & Dohme Corp. |
2016-05-25 |
| NCT02085083 |
Improving OutcoMes in the Pediatric to Adult Care Transition in Inflammatory Bowel Disease |
https://ClinicalTrials.gov/show/NCT02085083 |
Completed |
Mount Sinai Hospital, Canada |
2017-11-30 |
| NCT02084186 |
Moxibustion for Mild and Moderate Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02084186 |
Completed |
Shanghai Institute of Acupuncture, Moxibustion and Meridian |
2015-12-31 |
| NCT00450086 |
Budesonide Capsules vs. Mesalazine Granules vs. Placebo in Collagenous Colitis |
https://ClinicalTrials.gov/show/NCT00450086 |
Completed |
Dr. Falk Pharma GmbH |
2011-06-30 |
| NCT01294410 |
Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01294410 |
Completed |
Bristol-Myers Squibb |
2012-12-31 |
| NCT01290042 |
Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181. |
https://ClinicalTrials.gov/show/NCT01290042 |
Completed |
Amgen |
2014-04-30 |
| NCT01287195 |
Oral OKT3 for the Treatment of Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01287195 |
Completed |
Brigham and Women’s Hospital |
2013-05-02 |
| NCT01278082 |
SOIBD Collagenous Colitis Maintenance Study |
https://ClinicalTrials.gov/show/NCT01278082 |
Completed |
Dr. Falk Pharma GmbH |
2013-03-31 |
| NCT02049502 |
FMT in Ulcerative Colitis-Associated Pouchitis |
https://ClinicalTrials.gov/show/NCT02049502 |
Completed |
Emory University |
2018-02-01 |
| NCT02039505 |
Phase III Study of MLN0002 (300 mg) in the Treatment of Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02039505 |
Completed |
Takeda |
2018-02-27 |
| NCT04207008 |
Trial of a Decision Support Intervention for Adolescents and Young Adults With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT04207008 |
Recruiting |
Children’s Hospital Medical Center, Cincinnati |
2020-10-31 |
| NCT02020382 |
Evaluation of the Diagnostic Value of microRNAs for Inflammatory Bowel Diseases |
https://ClinicalTrials.gov/show/NCT02020382 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2016-12-31 |
| NCT03653026 |
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03653026 |
Recruiting |
AbbVie |
2021-02-23 |
| NCT01972334 |
Stool Transplant in Pediatric Patients With Recurring C. Difficile Infection |
https://ClinicalTrials.gov/show/NCT01972334 |
Completed |
MemorialCare Health System |
2016-07-31 |
| NCT01971814 |
Early Serum Infliximab Levels in Severe Ulcerative Colitis. |
https://ClinicalTrials.gov/show/NCT01971814 |
Completed |
University of California, San Francisco |
2015-01-31 |
| NCT01959282 |
A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01959282 |
Completed |
Janssen Research & Development, LLC |
2015-05-20 |
| NCT01959165 |
MEDI7183 Phase 2 Study in Japanese Ulcerative Colitis Patients |
https://ClinicalTrials.gov/show/NCT01959165 |
Completed |
AstraZeneca |
2015-08-11 |
| NCT01947101 |
Fecal Microbiota Transplantation (FMT) for Treatment of Ulcerative Colitis in Children |
https://ClinicalTrials.gov/show/NCT01947101 |
Completed |
Baylor College of Medicine |
2014-12-31 |
| NCT01900574 |
A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01900574 |
Active, not recruiting |
Janssen Research & Development, LLC |
2015-02-18 |
| NCT01896635 |
Faecal Microbiota Transplantation in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01896635 |
Completed |
The University of New South Wales |
2015-11-30 |
| NCT02025777 |
Evaluation of PillCam IBD Capsule Endoscopy System in Visualization of Lesions in the Colon Indicative of Ulcerative Colitis Disease |
https://ClinicalTrials.gov/show/NCT02025777 |
Completed |
Medtronic - MITG |
2015-06-30 |
| NCT01868373 |
Defined Fecal Microbiota Transplantation for Clostridium Difficile Diarrhea |
https://ClinicalTrials.gov/show/NCT01868373 |
Enrolling by invitation |
Baylor College of Medicine |
2022-02-28 |
| NCT01863771 |
A Safety and Effectiveness Study of Golimumab in Japanese Patients With Moderately to Severely Active Ulcerative Colitis. |
https://ClinicalTrials.gov/show/NCT01863771 |
Completed |
Janssen Pharmaceutical K.K. |
2016-01-29 |
| NCT01839214 |
A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01839214 |
Completed |
Vascular Biogenics Ltd. operating as VBL Therapeutics |
2014-11-30 |
| NCT01837615 |
Assessment of Photopill Capsule Treatment for Safety and Feasibility in Ulcerative Proctitis |
https://ClinicalTrials.gov/show/NCT01837615 |
Completed |
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
2015-05-31 |
| NCT01829321 |
Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of GLPG0974 in Subjects With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01829321 |
Completed |
Galapagos NV |
2014-04-30 |
| NCT01813526 |
Infants With Protein Sensitive Colitis |
https://ClinicalTrials.gov/show/NCT01813526 |
Completed |
Abbott Nutrition |
2001-02-28 |
| NCT01790061 |
Standardized Fecal Microbiota Transplantation for Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01790061 |
Recruiting |
The Second Hospital of Nanjing Medical University |
2022-12-31 |
| NCT04224857 |
SAD/MAD Study in Healthy Subjects and Adults With UC to Evaluate Safety, Tolerability, PK, PD of AMT-101 |
https://ClinicalTrials.gov/show/NCT04224857 |
Active, not recruiting |
Applied Molecular Transport |
2020-08-30 |
| NCT01772615 |
Treatment of Ulcerative Colitis With Ciprofloxacin and E. Coli Nissle |
https://ClinicalTrials.gov/show/NCT01772615 |
Completed |
Hvidovre University Hospital |
2013-08-31 |
| NCT01764542 |
Development of Dysplasia in the Pelvic Pouch in Patients With Ulcerative Colitis (UC) and Risk Factors |
https://ClinicalTrials.gov/show/NCT01764542 |
Completed |
Sahlgrenska University Hospital, Sweden |
2015-01-31 |
| NCT01771809 |
Long-Term Safety Of PF-00547659 In Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01771809 |
Completed |
Shire |
2017-12-13 |
| NCT01759056 |
Evaluation of an Oral Anti-TNF Antibody in Patients With Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01759056 |
Completed |
Avaxia Biologics, Incorporated |
2013-12-31 |
| NCT01757964 |
Bacteriotherapy in Pediatric Inflammatory Bowel Disease |
https://ClinicalTrials.gov/show/NCT01757964 |
Completed |
Seattle Children’s Hospital |
2013-10-31 |
| NCT01745770 |
TID 1000 mg Mesalazine Versus TID 2x500 mg Mesalazine in Active Ulcerative Colitis (UC) |
https://ClinicalTrials.gov/show/NCT01745770 |
Completed |
Dr. Falk Pharma GmbH |
2015-03-31 |
| NCT01716039 |
Pharmacokinetics of Adalimumab With Methotrexate for Treatment of Patients With Ulcerative Colitis (UC) |
https://ClinicalTrials.gov/show/NCT01716039 |
Active, not recruiting |
Western University, Canada |
2019-07-31 |
| NCT01694485 |
Abrilumab (AMG 181) in Adults With Moderate to Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01694485 |
Completed |
Amgen |
2015-07-13 |
| NCT01692743 |
Telemedicine in Patients With Inflammatory Bowel Disease (TELE-IBD) |
https://ClinicalTrials.gov/show/NCT01692743 |
Completed |
University of Maryland, Baltimore |
2015-07-31 |
| NCT01684514 |
Confocal Laser Endomicroscopy Findings in Patients With Proctosigmoiditis Before and After Initiation of Treatment |
https://ClinicalTrials.gov/show/NCT01684514 |
Completed |
Herlev Hospital |
2014-12-31 |
| NCT01670240 |
Adalimumab in the Treatment of Chronic Pouchitis |
https://ClinicalTrials.gov/show/NCT01670240 |
Completed |
Odense University Hospital |
2015-09-30 |
| NCT01647516 |
Efficacy and Safety Study of RPC1063 in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01647516 |
Completed |
Celgene |
2015-03-10 |
| NCT02043600 |
Randomized-controlled Trial of Yoga for Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02043600 |
Completed |
Universität Duisburg-Essen |
2015-05-31 |
| NCT01620255 |
A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01620255 |
Completed |
Shire |
2014-09-30 |
| NCT01612039 |
Safety, Efficacy, and Tolerability Study of ASP3291 in Patients With Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01612039 |
Completed |
Telsar Pharma Inc. |
2014-04-30 |
| NCT01585155 |
Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01585155 |
Completed |
Mitsubishi Tanabe Pharma Corporation |
2014-09-30 |
| NCT03999294 |
Bmgim Music Therapy Method in Reducing Stress in Patients With Inflammatory Bowel Disease |
https://ClinicalTrials.gov/show/NCT03999294 |
Completed |
University of Valencia |
2016-06-30 |
| NCT01561248 |
Study of Repetitive Intestinal Lavage in Patients With EHEC Associated Hemorrhagic Colitis |
https://ClinicalTrials.gov/show/NCT01561248 |
Completed |
Universitätsklinikum Hamburg-Eppendorf |
2011-06-30 |
| NCT01551290 |
A Study to Evaluate the Effectiveness and Safety of Infliximab in Chinese Patients With Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01551290 |
Completed |
Xian-Janssen Pharmaceutical Ltd. |
2014-03-31 |
| NCT01551004 |
Phase I Trial of a Single Dose of CRS3123 |
https://ClinicalTrials.gov/show/NCT01551004 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
2014-04-07 |
| NCT01550965 |
A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting |
https://ClinicalTrials.gov/show/NCT01550965 |
Completed |
AbbVie |
2015-04-30 |
| NCT01545908 |
Fecal Biotherapy for the Induction of Remission in Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01545908 |
Completed |
Hamilton Health Sciences Corporation |
2014-08-31 |
| NCT01536535 |
Predicting Response to Standardized Pediatric Colitis Therapy |
https://ClinicalTrials.gov/show/NCT01536535 |
Completed |
Connecticut Children’s Medical Center |
2018-04-30 |
| NCT01536509 |
Improving Medication Adherence in Pediatric Inflammatory Bowel Disease |
https://ClinicalTrials.gov/show/NCT01536509 |
Completed |
Children’s Hospital Medical Center, Cincinnati |
2016-05-31 |
| NCT01534312 |
Casein Glycomacropeptide in Active Distal Ulcerative Colitis (Pilot Study) |
https://ClinicalTrials.gov/show/NCT01534312 |
Completed |
University of Aarhus |
2014-09-30 |
| NCT01532648 |
Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA) |
https://ClinicalTrials.gov/show/NCT01532648 |
Completed |
Bausch Health Americas, Inc. |
2013-10-02 |
| NCT01506362 |
Efficacy, Pharmacodynamics, Safety and Tolerability of Oral BL-7040 in Patients With Moderately Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01506362 |
Completed |
BioLineRx, Ltd. |
2013-05-31 |
| NCT01505842 |
Chromoendoscopy for Dysplasia Detection in Chronic Inflammatory Bowel Disease |
https://ClinicalTrials.gov/show/NCT01505842 |
Active, not recruiting |
Karolinska University Hospital |
2019-04-04 |
| NCT01493960 |
The Efficacy and Safety of Cobitolimod (Kappaproct®) in Chronic Active Treatment Refractory Ulcerative Colitis Patients |
https://ClinicalTrials.gov/show/NCT01493960 |
Completed |
InDex Pharmaceuticals |
2013-06-30 |
| NCT01482884 |
Evaluation of Efficacy and Safety of Tralokinumab in Patients With Active, Moderate-to-severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01482884 |
Completed |
AstraZeneca |
2013-03-31 |
| NCT01481142 |
Adacolumn in Refractory UC Patients Trial |
https://ClinicalTrials.gov/show/NCT01481142 |
Completed |
Otsuka Pharmaceutical Europe Ltd |
2015-05-31 |
| NCT01477320 |
Enteral Nutrition as Stress Ulcer Prophylaxis in Critically Ill Patients. |
https://ClinicalTrials.gov/show/NCT01477320 |
Completed |
University of Louisville |
2016-07-31 |
| NCT01470612 |
Long-Term Study Of CP-690,550 In Subjects With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01470612 |
Active, not recruiting |
Pfizer |
2020-07-27 |
| NCT01461317 |
Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01461317 |
Completed |
Genentech, Inc. |
2016-08-07 |
| NCT01458951 |
A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01458951 |
Completed |
Pfizer |
2015-05-31 |
| NCT01458574 |
A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01458574 |
Completed |
Pfizer |
2016-05-27 |
| NCT01456052 |
A Study to Evaluate Safety and Efficacy of Telotristat Etiprate (LX1606) in Participants With Acute, Mild to Moderate Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01456052 |
Completed |
Lexicon Pharmaceuticals |
2013-09-03 |
| NCT01453491 |
A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01453491 |
Completed |
GlaxoSmithKline |
2013-03-18 |
| NCT01433471 |
Mucosal Immunity of Ulcerative Colitis Patients Undergoing Therapy With Trichuris Suis Ova |
https://ClinicalTrials.gov/show/NCT01433471 |
Completed |
NYU Langone Health |
2015-05-31 |
| NCT03189888 |
Granulocyte-monocyte Apheresis in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03189888 |
Completed |
Valduce Hospital |
2013-12-31 |
| NCT01418131 |
Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis |
https://ClinicalTrials.gov/show/NCT01418131 |
Completed |
The University of Western Australia |
2016-09-30 |
| NCT03832400 |
Safety and Efficacy of Microbial Ecosystem Therapeutic-2 (MET-2) in Patients With Ulcerative Colitis (UC) |
https://ClinicalTrials.gov/show/NCT03832400 |
Recruiting |
NuBiyota |
2019-11-30 |
| NCT01408810 |
Evaluation of Histologic and Endoscopic Remission Induced by Infliximab in Moderate to Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01408810 |
Completed |
Grupo de Estudo da Doença Inflamatória Intestinal |
2012-11-30 |
| NCT01393405 |
Methotrexate in Induction and Maintenance of Steroid Free Remission in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01393405 |
Completed |
University of North Carolina, Chapel Hill |
2017-04-30 |
| NCT01387594 |
Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn’s Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs |
https://ClinicalTrials.gov/show/NCT01387594 |
Completed |
Shire |
2014-03-31 |
| NCT01369355 |
A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn’s Disease (IM-UNITI) |
https://ClinicalTrials.gov/show/NCT01369355 |
Completed |
Janssen Research & Development, LLC |
2015-06-10 |
| NCT01369342 |
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn’s Disease (UNITI-2) |
https://ClinicalTrials.gov/show/NCT01369342 |
Completed |
Janssen Research & Development, LLC |
2014-08-31 |
| NCT01346826 |
Safety of Accelerated Infliximab Infusions in Patients With Inflammatory Bowel Disease (IBD) |
https://ClinicalTrials.gov/show/NCT01346826 |
Completed |
Asan Medical Center |
2015-10-31 |
| NCT01341808 |
Immunogenicity of Hepatitis A Vaccine in Inflammatory Bowel Disease (IBD) Patients |
https://ClinicalTrials.gov/show/NCT01341808 |
Completed |
Asan Medical Center |
2013-02-28 |
| NCT01336465 |
Evaluate the Efficacy and Safety of rhuMAb Beta7 in Patients With Moderate to Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01336465 |
Completed |
Genentech, Inc. |
2012-09-30 |
| NCT01320436 |
Curcumin + Aminosalicylic Acid (5ASA) Versus 5ASA Alone in the Treatment of Mild to Moderate Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01320436 |
Completed |
Sheba Medical Center |
2014-09-30 |
| NCT01320332 |
A Study of a Single Dose of ASP3291 in Subjects With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01320332 |
Completed |
Telsar Pharma Inc. |
2011-08-31 |
| NCT04191655 |
High Definition Colonoscopy (HDC) vs. Dye Spraying Chromo-colonoscopy (DSC) in Screening Patients With Long-standing Inflammatory Bowel Disease (IBD) |
https://ClinicalTrials.gov/show/NCT04191655 |
Recruiting |
Beth Israel Deaconess Medical Center |
2021-10-31 |
| NCT04340895 |
Study to Assess Effectiveness of Therapy Timely Adjustment Based on Self-monitoring in Patients Suffering From Mild-to-moderate Ulcerative Colitis (OPTIMISE Study) |
https://ClinicalTrials.gov/show/NCT04340895 |
Recruiting |
Ferring Pharmaceuticals |
2021-12-31 |
| NCT04329481 |
The Effect of Mycobiome Supplementation on Gastrointestinal Symptoms in IBD Patients |
https://ClinicalTrials.gov/show/NCT04329481 |
Recruiting |
Tel-Aviv Sourasky Medical Center |
2022-06-12 |
| NCT04259138 |
Determination of the Optimal Treatment Target in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT04259138 |
Recruiting |
Robarts Clinical Trials Inc. |
2024-11-30 |
| NCT04254783 |
A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease |
https://ClinicalTrials.gov/show/NCT04254783 |
Recruiting |
AbbVie |
2021-07-02 |
| NCT04241029 |
Boosting Biologics in UC |
https://ClinicalTrials.gov/show/NCT04241029 |
Recruiting |
Oslo University Hospital |
2021-06-30 |
| NCT04237181 |
Results of FilmArray® Gastro-intestinal Panel and Serum Procalcitonin in Acute Colitis and Infectious Diarrhea in the ER |
https://ClinicalTrials.gov/show/NCT04237181 |
Recruiting |
Assistance Publique - Hôpitaux de Paris |
2021-03-15 |
| NCT04223479 |
Effect of Probiotic Supplementation on the Immune System in Patients With Ulcerative Colitis in Amman, Jordan |
https://ClinicalTrials.gov/show/NCT04223479 |
Recruiting |
University of Jordan |
2021-11-30 |
| NCT04183608 |
A Trial COmparing staNdard of Care Versus Treat to Target With telemonitoRing and Patient Education in Patients With Ulcerative cOlitis Initiating Adalimumab |
https://ClinicalTrials.gov/show/NCT04183608 |
Recruiting |
Groupe d’Etude Therapeutique des Affections Inflammatoires Digestives |
2022-01-31 |
| NCT04209556 |
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT04209556 |
Recruiting |
Pfizer |
2023-10-26 |
| NCT04165265 |
The Use of Web-app Constant-Care in Patients With Acute Severe Ulcerative Colitis Treated With Rescue Therapy |
https://ClinicalTrials.gov/show/NCT04165265 |
Recruiting |
Nordsjaellands Hospital |
2021-06-30 |
| NCT04159311 |
Osteopathy on IBS Symptoms in Patients With Ulcerative Colitis in Remission |
https://ClinicalTrials.gov/show/NCT04159311 |
Recruiting |
Clinique Paris-Bercy |
2021-11-02 |
| NCT04147598 |
Diet Study on Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT04147598 |
Completed |
University of Miami |
2018-09-11 |
| NCT04143633 |
Low FODMAP Diet on Nutritional Status, Disease Activity and Gut Microbiota in IBS and UC With Normal or Overweight BMI |
https://ClinicalTrials.gov/show/NCT04143633 |
Recruiting |
Hospital General de Mexico |
2020-08-31 |
| NCT04143490 |
Effects of Exercise in Patients With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT04143490 |
Recruiting |
Manchester Metropolitan University |
2020-09-30 |
| NCT04133194 |
Adherence of a 1.600 mg Single Tablet 5-ASA Treatment of Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT04133194 |
Recruiting |
Copenhagen University Hospital, Hvidovre |
2022-09-30 |
| NCT04130919 |
Study to Evaluate the Efficacy and Safety of GS-4875 in Adults With Moderately to Severely Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT04130919 |
Recruiting |
Gilead Sciences |
2021-04-30 |
| NCT04114292 |
TUDCA as a Therapy for Ulcerative Colitis (UC) |
https://ClinicalTrials.gov/show/NCT04114292 |
Recruiting |
Washington University School of Medicine |
2020-12-31 |
| NCT04057547 |
Efficacy and Safety of Modified Gegen Qinlian Decoction for Ulcerative Colitis With Damp-heat Syndrome |
https://ClinicalTrials.gov/show/NCT04057547 |
Recruiting |
Xiyuan Hospital of China Academy of Chinese Medical Sciences |
2019-07-01 |
| NCT04043897 |
Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis |
https://ClinicalTrials.gov/show/NCT04043897 |
Recruiting |
NorthShore University HealthSystem |
2020-04-30 |
| NCT04030676 |
QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT04030676 |
Recruiting |
Centre Hospitalier Universitaire de Saint Etienne |
2021-01-31 |
| NCT04023396 |
Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT04023396 |
Recruiting |
Abivax S.A. |
2021-11-30 |
| NCT04018040 |
Vegetarian Diet in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT04018040 |
Recruiting |
Edith Cowan University |
2021-12-31 |
| NCT04013152 |
Clinical Database of Colorectal Robotic Surgery |
https://ClinicalTrials.gov/show/NCT04013152 |
Recruiting |
Institut du Cancer de Montpellier - Val d’Aurelle |
2021-01-31 |
| NCT04006080 |
Investigation of the Faecal Loss of Vedolizumab and Its Role in Influencing Serum Drug Levels, Outcomes and Response in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT04006080 |
Recruiting |
Guy’s and St Thomas’ NHS Foundation Trust |
2020-03-31 |
| NCT04003818 |
Efficacy and Safety of Teicoplanin in CDAD |
https://ClinicalTrials.gov/show/NCT04003818 |
Recruiting |
Sanofi |
2022-04-30 |
| NCT04000139 |
Anthocyanin Rich Extract (ACRE) in Patients With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT04000139 |
Recruiting |
University of Zurich |
2020-11-30 |
| NCT03998488 |
Examining the Efficacy of Fecal Microbiota Transplantation (FMT) and Dietary Fiber in Patients With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03998488 |
Active, not recruiting |
Weill Medical College of Cornell University |
2023-01-31 |
| NCT03948919 |
Low Sulfur Fecal Transplant for Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03948919 |
Recruiting |
University of Minnesota |
2020-12-31 |
| NCT03943550 |
Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Patients With Ulcerative Colitis (UC) |
https://ClinicalTrials.gov/show/NCT03943550 |
Recruiting |
Hoffmann-La Roche |
2021-04-07 |
| NCT03934216 |
Safety and Efficacy of BMS-986165 in Subjects With Moderate to Severe Ulcerative Colitis (UC) |
https://ClinicalTrials.gov/show/NCT03934216 |
Recruiting |
Bristol-Myers Squibb |
2021-08-16 |
| NCT03923478 |
ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03923478 |
Recruiting |
Assembly Biosciences |
2021-06-30 |
| NCT03917095 |
The Safety and Efficacy of TET Enema in the Treatment of UC |
https://ClinicalTrials.gov/show/NCT03917095 |
Recruiting |
The Second Hospital of Nanjing Medical University |
2019-06-15 |
| NCT03915769 |
To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03915769 |
Recruiting |
Celgene |
2021-07-23 |
| NCT03912714 |
COlonic Salvage by Therapeutic Appendectomy. |
https://ClinicalTrials.gov/show/NCT03912714 |
Recruiting |
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
2020-09-30 |
| NCT03908073 |
Electrical Vagal Nerve Stimulation in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03908073 |
Recruiting |
Queen Mary University of London |
2020-06-15 |
| NCT03893565 |
Safety, Tolerability, Efficacy and Dose-response of GSK2831781 in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03893565 |
Recruiting |
GlaxoSmithKline |
2022-04-19 |
| NCT03885713 |
Identification of Predictive Biomarkers for Response to Biologic Therapies in Inflammatory Bowel Disease |
https://ClinicalTrials.gov/show/NCT03885713 |
Recruiting |
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa |
2021-08-31 |
| NCT03104036 |
Faecal Bacteriotherapy for Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03104036 |
Recruiting |
Institute for Clinical and Experimental Medicine |
2020-06-30 |
| NCT03863886 |
Endoscopic Ultrasound Determines Disease Activity in Crohn’s Disease And Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03863886 |
Recruiting |
Carilion Clinic |
2020-01-31 |
| NCT03861143 |
Efficacy and Safety of Oral BT-11 in Mild to Moderate Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03861143 |
Recruiting |
Landos Biopharma Inc. |
2020-06-30 |
| NCT03860896 |
GB004 in Adult Subjects With Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03860896 |
Completed |
Gossamer Bio Inc. |
2019-12-17 |
| NCT03849599 |
A Study to Evaluate the Safety of PRV-300 in Adult Subjects With Moderately to Severely Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03849599 |
Completed |
Provention Bio, Inc. |
2019-03-01 |
| NCT03844932 |
A Study Evaluating the Efficacy and Safety of ST-0529 in Subjects With Moderately to Severely Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03844932 |
Recruiting |
Sublimity Therapeutics Holdco Limited |
2020-11-30 |
| NCT03804931 |
Fecal Microbiota Transplantation for Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03804931 |
Recruiting |
Guangzhou First People’s Hospital |
2028-12-31 |
| NCT03800420 |
Efficacy and Safety of BBT-401-1S in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03800420 |
Active, not recruiting |
Bridge Biotherapeutics, Inc. |
2020-05-18 |
| NCT03798210 |
Lactobacillus Reuteri ATCC PTA 4659 in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03798210 |
Recruiting |
Uppsala University |
2019-01-31 |
| NCT03781284 |
PET Combined With MRI for Monitoring Inflammatory Activity in Patients With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03781284 |
Completed |
Universität Duisburg-Essen |
2018-10-31 |
| NCT03006068 |
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) |
https://ClinicalTrials.gov/show/NCT03006068 |
Enrolling by invitation |
AbbVie |
2022-01-07 |
| NCT03768219 |
Study to Evaluate APVO210 in Healthy Subjects, Patients With Psoriasis, and Patients With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03768219 |
Active, not recruiting |
Aptevo Therapeutics |
2020-09-30 |
| NCT03760003 |
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03760003 |
Recruiting |
Abivax S.A. |
2020-06-30 |
| NCT03759041 |
A Study to Assess Efficacy and Safety of SER‑287 in Adults With Active Mild-to-Moderate Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03759041 |
Recruiting |
Seres Therapeutics, Inc. |
2020-07-31 |
| NCT03756454 |
Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery. |
https://ClinicalTrials.gov/show/NCT03756454 |
Recruiting |
Ohio State University |
2021-07-31 |
| NCT03724929 |
Value of Pharmacokinetic Assays in the Prediction of Therapeutic Response in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03724929 |
Recruiting |
Centre Hospitalier Universitaire de Saint Etienne |
2021-09-30 |
| NCT03724175 |
The Role of Secondary Bile Acids in Intestinal Inflammation |
https://ClinicalTrials.gov/show/NCT03724175 |
Recruiting |
Stanford University |
2025-12-31 |
| NCT03720002 |
HF2 Therapy in the Treatment of Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03720002 |
Recruiting |
Sheba Medical Center |
2021-01-31 |
| NCT03773952 |
Safety and Efficacy of PBF-677 in Ulcerative Colitis Patients |
https://ClinicalTrials.gov/show/NCT03773952 |
Recruiting |
Palobiofarma SL |
2020-06-30 |
| NCT03716388 |
Fecal Microbiota Therapy Vs 5-aminosalicylates for Induction of Remission in Newly Diagnosed Mild-moderately Active UC |
https://ClinicalTrials.gov/show/NCT03716388 |
Recruiting |
Dayanand Medical College and Hospital |
2019-12-01 |
| NCT03711006 |
The Effect of Fecal Microbiota Transplantation in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03711006 |
Completed |
Aleris-Hamlet Hospitaler København |
2017-11-30 |
| NCT03705117 |
Open-label V565 Target Engagement Study |
https://ClinicalTrials.gov/show/NCT03705117 |
Completed |
VHsquared Ltd. |
2017-10-24 |
| NCT03698500 |
Specific microRNAs as Potential Biomarker for Inflammatory Bowel Disease |
https://ClinicalTrials.gov/show/NCT03698500 |
Recruiting |
University Hospital Muenster |
2020-12-31 |
| NCT03695185 |
A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy |
https://ClinicalTrials.gov/show/NCT03695185 |
Recruiting |
AbbVie |
2020-12-18 |
| NCT03679546 |
EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis |
https://ClinicalTrials.gov/show/NCT03679546 |
Recruiting |
Rennes University Hospital |
2021-01-04 |
| NCT03675477 |
A Phase II Study in Patients With Moderate to Severe Active Ulcerative Colitis. |
https://ClinicalTrials.gov/show/NCT03675477 |
Recruiting |
Reistone Biopharma Company Limited |
2020-07-31 |
| NCT03656627 |
Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease |
https://ClinicalTrials.gov/show/NCT03656627 |
Recruiting |
Alliance Foundation Trials, LLC. |
2022-10-31 |
| NCT02291523 |
The Effect of Therapeutic Fecal Transplant on the Gut Microbiome in Children With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02291523 |
Recruiting |
Children’s Hospital Los Angeles |
2021-11-30 |
| NCT03609905 |
Adipose Mesenchymal Stem Cells (AMSC) for Treatment of Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03609905 |
Recruiting |
Liaocheng People’s Hospital |
2019-02-01 |
| NCT03601611 |
Checkpoint Inhibitor Induced Colitis and Arthritis -Immunomodulation With IL-6 Blockade and Exploration of Disease Mechanisms |
https://ClinicalTrials.gov/show/NCT03601611 |
Completed |
Herlev Hospital |
2020-01-28 |
| NCT03587519 |
Short or Long Interval to Ileostomy Reversal After Ileal Pouch Surgery |
https://ClinicalTrials.gov/show/NCT03587519 |
Enrolling by invitation |
University of Colorado, Denver |
2021-01-01 |
| NCT03582969 |
Capsulized Fecal Microbiota Transplantation in Pediatric Ulcerative Colitis Patients |
https://ClinicalTrials.gov/show/NCT03582969 |
Recruiting |
Assaf-Harofeh Medical Center |
2021-07-31 |
| NCT03581149 |
Tolerability and Efficacy of Sodium Picosulfate/Magnesium Citrate Versus PEG/Ascorbic Acid in Ulcerative Colitis Patients |
https://ClinicalTrials.gov/show/NCT03581149 |
Recruiting |
American University of Beirut Medical Center |
2020-07-26 |
| NCT03565939 |
Probiotic Treatment of Ulcerative Colitis With Trichuris Suis Ova (TSO) |
https://ClinicalTrials.gov/show/NCT03565939 |
Recruiting |
ParaTech A/S |
2021-12-31 |
| NCT03561532 |
Fecal Transplantation in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03561532 |
Active, not recruiting |
Joint Authority for Päijät-Häme Social and Health Care |
2020-05-31 |
| NCT03538366 |
Fecal Microbiota Transplantation for Chronic Pouchitis |
https://ClinicalTrials.gov/show/NCT03538366 |
Completed |
Aalborg University Hospital |
2019-05-01 |
| NCT03536988 |
TAMIS-IPAA vs. Lap-IPAA for Ulcerative Colitiis |
https://ClinicalTrials.gov/show/NCT03536988 |
Recruiting |
Jinling Hospital, China |
2020-09-01 |
| NCT03531892 |
A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03531892 |
Recruiting |
Eisai Inc. |
2020-11-30 |
| NCT03494764 |
Hyperbaric Oxygen Therapy for Ulcerative Colitis Flares |
https://ClinicalTrials.gov/show/NCT03494764 |
Active, not recruiting |
Dartmouth-Hitchcock Medical Center |
2020-09-01 |
| NCT03483246 |
Impact of Fecal Microbiota Transplantation in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03483246 |
Recruiting |
Assistance Publique - Hôpitaux de Paris |
2021-09-30 |
| NCT03478956 |
A Phase I Study Of Etrolizumab Followed By Open-Label Extension And Safety Monitoring In Pediatric Patients With Moderate To Severe Ulcerative Colitis Or Moderate To Severe Crohn’s Disease |
https://ClinicalTrials.gov/show/NCT03478956 |
Active, not recruiting |
Hoffmann-La Roche |
2019-12-02 |
| NCT03441893 |
Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03441893 |
Active, not recruiting |
Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan |
2025-07-01 |
| NCT03427229 |
Fecal Microbiota Transplantation for Severe Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT03427229 |
Completed |
Catholic University of the Sacred Heart |
2017-10-30 |
| NCT03412682 |
To Evaluate the Efficacy and Safety of FE 999315 in Japanese Subjects With Mild to Moderate Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03412682 |
Completed |
Ferring Pharmaceuticals |
2020-05-11 |
| NCT01257399 |
Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase |
https://ClinicalTrials.gov/show/NCT01257399 |
Completed |
Tillotts Pharma AG |
2013-01-31 |
| NCT01257386 |
Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01257386 |
Completed |
Tillotts Pharma AG |
2012-08-31 |
| NCT01245465 |
Profermin® in Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01245465 |
Completed |
Nordisk Rebalance A/S |
2009-11-30 |
| NCT01240915 |
A Study To Investigate The Safety And Possible Clinical Benefit Of Multistem(r) In Patients With Moderate To Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01240915 |
Completed |
Pfizer |
2014-11-30 |
| NCT01209208 |
Budesonide Versus Mesalazine Versus Placebo in Lymphocytic Colitis |
https://ClinicalTrials.gov/show/NCT01209208 |
Completed |
Dr. Falk Pharma GmbH |
2017-06-30 |
| NCT01201122 |
Once Versus Twice Daily Mesalamine to Induce Remission in Pediatric Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01201122 |
Completed |
Wolfson Medical Center |
2015-12-31 |
| NCT01193894 |
Trial on Profermin and Fresubin in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01193894 |
Completed |
Nordisk Rebalance A/S |
2012-09-30 |
| NCT01177228 |
Study of Vedolizumab Following Multiple Intravenous Doses in Patients With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01177228 |
Completed |
Millennium Pharmaceuticals, Inc. |
2008-06-30 |
| NCT01149707 |
Safety, Tolerability, Efficacy Study of PUR 0110 Rectal Enema in Mild-to-Moderate Distal Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01149707 |
Completed |
PurGenesis Technologies Inc. |
2014-10-01 |
| NCT01149694 |
A Study to Assess the Safety and Tolerability of PUR 0110 Rectal Enema in Normal Healthy Volunteers |
https://ClinicalTrials.gov/show/NCT01149694 |
Completed |
PurGenesis Technologies Inc. |
2009-08-31 |
| NCT01130844 |
Safety and Pharmacokinetics of MMX Mesalamine in Children and Adolescents With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01130844 |
Completed |
Shire |
2013-06-30 |
| NCT01124149 |
Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01124149 |
Completed |
Shire |
2012-12-07 |
| NCT01100112 |
(CB-01-02/06) Oral Budesonide-Multi-Matrix System (MMX) 9mg Extended Release Tablets |
https://ClinicalTrials.gov/show/NCT01100112 |
Completed |
Bausch Health Americas, Inc. |
2010-07-31 |
| NCT01097590 |
A Study to Evaluate a Leukapheresis Treatment in Patients With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01097590 |
Completed |
IBD Column Therapies International AB |
2011-10-31 |
| NCT01090154 |
Study of Cimzia for the Treatment of Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01090154 |
Active, not recruiting |
University of Washington |
2019-12-31 |
| NCT01065571 |
Effects of Carrageenan-Elimination Diet on Ulcerative Colitis Disease Activity |
https://ClinicalTrials.gov/show/NCT01065571 |
Completed |
University of Illinois at Chicago |
2013-12-31 |
| NCT01059344 |
Efficacy and Safety of Asacolâ„¢ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01059344 |
Completed |
Tillotts Pharma AG |
2011-07-31 |
| NCT01037322 |
Cannabidiol for Inflammatory Bowel Disease |
https://ClinicalTrials.gov/show/NCT01037322 |
Completed |
Meir Medical Center |
2012-09-30 |
| NCT01033305 |
Oral Ciclosporin for Colonic Release in Ulcerative Colitis (CyColâ„¢) |
https://ClinicalTrials.gov/show/NCT01033305 |
Completed |
Sigmoid Pharma |
2011-08-31 |
| NCT01026857 |
Propionyl-L-Carnitine in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01026857 |
Completed |
sigma-tau i.f.r. S.p.A. |
2009-04-30 |
| NCT01020708 |
Study of the Safety and Tolerability of ALTH12 Versus Mesalamine Enema in Subjects With Left-Sided Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01020708 |
Completed |
Altheus Therapeutics, Inc. |
2010-09-30 |
| NCT00963287 |
Trial of Chinese Prescription on Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00963287 |
Completed |
Shanghai University of Traditional Chinese Medicine |
2011-07-31 |
| NCT00951548 |
Food Supplementation With VSL#3 as a Support to Standard Pharmaceutical Therapy in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00951548 |
Completed |
VSL Pharmaceuticals |
NA |
| NCT00952952 |
Trial of Mesalamine for the Treatment of Active Microscopic Colitis |
https://ClinicalTrials.gov/show/NCT00952952 |
Completed |
Mayo Clinic |
2007-11-30 |
| NCT00940576 |
Dietetic Efficacy of Mare’s Milk for Patients With Chronic Inflammatory Bowel Diseases |
https://ClinicalTrials.gov/show/NCT00940576 |
Completed |
University of Jena |
2001-02-28 |
| NCT00928681 |
A Study To Investigate The Safety And Efficacy Properties Of PF-00547659 In Patients With Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00928681 |
Completed |
Pfizer |
2008-04-30 |
| NCT00922103 |
A Study to Investigate the Ileo Neo Rectal Anastomosis Compared to the Ileo Pouch Anal Anastomosis for Patients With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00922103 |
Completed |
Elisabeth-TweeSteden Ziekenhuis |
2009-12-31 |
| NCT03869905 |
Aquamin® as an Adjuvant Intervention for Ulcerative Colitis In Remission |
https://ClinicalTrials.gov/show/NCT03869905 |
Recruiting |
University of Michigan |
2022-12-31 |
| NCT00853099 |
A Study of Adalimumab in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00853099 |
Completed |
AbbVie |
2011-05-31 |
| NCT04102852 |
Lactobacillus Rhamnosus GG (ATCC 53103) in Mild-moderately Active UC Patients |
https://ClinicalTrials.gov/show/NCT04102852 |
Recruiting |
San Giovanni Addolorata Hospital |
2020-09-30 |
| NCT02127398 |
Stool Transplants to Treat Refractory Clostridium Difficile Colitis |
https://ClinicalTrials.gov/show/NCT02127398 |
Recruiting |
Duke University |
2022-05-31 |
| NCT02033408 |
Manipulating the Microbiome in IBD by Antibiotics and FMT |
https://ClinicalTrials.gov/show/NCT02033408 |
Active, not recruiting |
Shaare Zedek Medical Center |
2018-12-31 |
| NCT01804166 |
A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn’s Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) |
https://ClinicalTrials.gov/show/NCT01804166 |
Completed |
Janssen Scientific Affairs, LLC |
2020-02-29 |
| NCT01491997 |
Mind-Body Medicine and Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01491997 |
Completed |
Rush University Medical Center |
2017-07-31 |
| NCT03794765 |
Antibiotics as an Adjuvant in Patients With Acute Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03794765 |
Completed |
Postgraduate Institute of Medical Education and Research |
2020-03-04 |
| NCT03232528 |
The Promotion Plan of Moxibustion on Ulcerate Colitis |
https://ClinicalTrials.gov/show/NCT03232528 |
Recruiting |
Shanghai Institute of Acupuncture, Moxibustion and Meridian |
2018-12-30 |
| NCT02921555 |
Endovenous Corticosteroid Pulses in Moderate Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02921555 |
Recruiting |
Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa |
2019-11-30 |
| NCT02445365 |
Remote Ischemic Conditioning in Patients With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02445365 |
Completed |
Odense University Hospital |
2018-02-28 |
| NCT01988961 |
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01988961 |
Completed |
Janssen Research & Development, LLC |
2015-02-28 |
| NCT01284062 |
Pharmacokinetics/Pharmacodynamics Biomarker Study in Active Ulcerative Colitis Patients |
https://ClinicalTrials.gov/show/NCT01284062 |
Completed |
Pfizer |
2013-04-30 |
| NCT00829595 |
Pneumococcal Vaccination in Patients With Inflammatory Bowel Disease |
https://ClinicalTrials.gov/show/NCT00829595 |
Completed |
Cedars-Sinai Medical Center |
2007-12-31 |
| NCT00810030 |
FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR |
https://ClinicalTrials.gov/show/NCT00810030 |
Completed |
Vifor (International) Inc. |
2009-12-31 |
| NCT00808977 |
A Phase II Study to Explore the Safety and Activity of Dersalazine in Patients With Mild to Moderate Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00808977 |
Completed |
Palau Pharma S.A. |
2010-06-30 |
| NCT01860651 |
Web-based Monitoring in Children and Adolescents With Inflammatory Bowel Disease |
https://ClinicalTrials.gov/show/NCT01860651 |
Completed |
Hvidovre University Hospital |
2017-05-31 |
| NCT01520324 |
Neoplasia Detection With Methylene Blue MMX Tablets in Patients With UC Undergoing Colonoscopy |
https://ClinicalTrials.gov/show/NCT01520324 |
Completed |
CosmoTech |
2012-07-31 |
| NCT03558152 |
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC) |
https://ClinicalTrials.gov/show/NCT03558152 |
Recruiting |
Genentech, Inc. |
2021-08-11 |
| NCT00803829 |
Synbiotic Treatment of Ulcerative Colitis Patients |
https://ClinicalTrials.gov/show/NCT00803829 |
Completed |
University of Dundee |
2011-01-31 |
| NCT00801723 |
(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis. |
https://ClinicalTrials.gov/show/NCT00801723 |
Completed |
Bausch Health Americas, Inc. |
2011-05-31 |
| NCT03368118 |
Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03368118 |
Active, not recruiting |
Abivax S.A. |
2019-03-08 |
| NCT03100864 |
This Study Tests How BI 655130 Works in Patients With Active Ulcerative Colitis. The Study Also Tests How Well BI 655130 is Tolerated and Whether it Helps the Patients |
https://ClinicalTrials.gov/show/NCT03100864 |
Completed |
Boehringer Ingelheim |
2019-08-05 |
| NCT03018054 |
Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03018054 |
Completed |
Eisai Inc. |
2019-04-17 |
| NCT03273465 |
Fecal Microbiota Transplantation in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03273465 |
Recruiting |
Assaf-Harofeh Medical Center |
2020-04-30 |
| NCT03123120 |
A Study in Patients With Mild or Moderate Ulcerative Colitis Who Take a TNF Inhibitor. The Study Investigates Whether Bowel Inflammation Improves When Patients Take BI 655130 in Addition to Their Current Therapy |
https://ClinicalTrials.gov/show/NCT03123120 |
Active, not recruiting |
Boehringer Ingelheim |
2020-03-26 |
| NCT03053713 |
The Effect of Diet on Disease Activity and Symptoms in Patients With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03053713 |
Enrolling by invitation |
University of British Columbia |
2020-04-01 |
| NCT02943538 |
Telemedicine Crohn’s Disease and Ulcerative Colitis (TECCU) |
https://ClinicalTrials.gov/show/NCT02943538 |
Completed |
Instituto de Investigacion Sanitaria La Fe |
2016-12-31 |
| NCT02865707 |
Ulcerative Colitis Relapse Prevention by Prebiotics |
https://ClinicalTrials.gov/show/NCT02865707 |
Recruiting |
University of Alberta |
2020-02-29 |
| NCT02065622 |
Study to Evaluate the Safety and Efficacy of Two Drug Regimens in Subjects With Moderate to Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02065622 |
Completed |
AbbVie |
2019-09-05 |
| NCT02818686 |
TD-1473 for Active Ulcerative Colitis (UC) |
https://ClinicalTrials.gov/show/NCT02818686 |
Completed |
Theravance Biopharma |
2018-03-31 |
| NCT03758443 |
Efficacy & Safety of TD-1473 in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03758443 |
Recruiting |
Theravance Biopharma |
2025-06-30 |
| NCT02601300 |
An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02601300 |
Completed |
Celgene |
2016-09-06 |
| NCT02745678 |
Localized Therapeutics for the Treatment of Gastrointestinal Disorders II |
https://ClinicalTrials.gov/show/NCT02745678 |
Completed |
Stanford University |
2017-11-30 |
| NCT03977480 |
Phase II Study of Hemay007 in Patients With Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT03977480 |
Recruiting |
Tianjin Hemay Pharmaceutical Co.,Ltd |
2020-12-31 |
| NCT02522767 |
Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC) |
https://ClinicalTrials.gov/show/NCT02522767 |
Completed |
Ferring Pharmaceuticals |
2018-02-06 |
| NCT02508012 |
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases |
https://ClinicalTrials.gov/show/NCT02508012 |
Active, not recruiting |
University Hospital, Montpellier |
2020-09-23 |
| NCT01903252 |
TP05 for the Treatment of Mild to Moderate Active Ulcerative Colitis (UC) |
https://ClinicalTrials.gov/show/NCT01903252 |
Completed |
Tillotts Pharma AG |
2016-05-31 |
| NCT01831427 |
Evaluating the Safety, Pharmacokinetics and Efficacy of GS-5745 in Adults With Moderately to Severely Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT01831427 |
Completed |
Gilead Sciences |
2015-02-06 |
| NCT00867438 |
Efficacy and Tolerability of a New Oral Extended-Release Formulation Containing Parnaparin Sodium, Administered Add-on Therapy |
https://ClinicalTrials.gov/show/NCT00867438 |
Completed |
CosmoTech |
2007-11-30 |
| NCT01650038 |
Transplantation of Faeces in Ulcerative Colitis; Restoring Nature’s Homeostasis |
https://ClinicalTrials.gov/show/NCT01650038 |
Completed |
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) |
2014-08-31 |
| NCT01929668 |
Comparison of 4L Polyethylene Glycol and 2L Polyethylene Glycol With Ascorbic Acid in Inactive UC Patients |
https://ClinicalTrials.gov/show/NCT01929668 |
Completed |
Kyungpook National University Hospital |
2014-12-31 |
| NCT03650413 |
An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn’s Disease |
https://ClinicalTrials.gov/show/NCT03650413 |
Recruiting |
Genentech, Inc. |
2022-12-17 |
| NCT02469220 |
Diet Treatment of Patients With Ulcerative Colitis in Remission |
https://ClinicalTrials.gov/show/NCT02469220 |
Active, not recruiting |
Vendsyssel Hospital |
2020-07-31 |
| NCT00783718 |
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00783718 |
Completed |
Millennium Pharmaceuticals, Inc. |
2011-12-31 |
| NCT00790933 |
An Open-label Study of Vedolizumab (MLN0002) in Participants With Ulcerative Colitis and Crohn’s Disease |
https://ClinicalTrials.gov/show/NCT00790933 |
Completed |
Takeda |
2017-10-31 |
| NCT00787202 |
A Study To Investigate The Safety And Efficacy Of CP- 690,550 In Patients With Moderate And Severe Ulcerative Colitis. |
https://ClinicalTrials.gov/show/NCT00787202 |
Completed |
Pfizer |
2010-09-30 |
| NCT00781638 |
ADAPT Adacolumn Pediatric Trial in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00781638 |
Completed |
Otsuka Frankfurt Research Institute GmbH |
2012-03-31 |
| NCT00746447 |
Once Daily (OD) Versus Three Times Daily (TID) Dosing With Mesalazine Granules for Prevention of Recurrence of Ulcerative Colitis (UC) |
https://ClinicalTrials.gov/show/NCT00746447 |
Completed |
Dr. Falk Pharma GmbH |
2007-04-30 |
| NCT00767728 |
Mesalamine Pellet to Maintain Remission of Mild to Moderate Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00767728 |
Completed |
Bausch Health Americas, Inc. |
2007-08-31 |
| NCT00747110 |
Budesonide Capsules Versus Mesalazine Granules in Active Ulcerative Colitis (UC) |
https://ClinicalTrials.gov/show/NCT00747110 |
Completed |
Dr. Falk Pharma GmbH |
2008-08-31 |
| NCT00744016 |
Mesalamine Pellet Formulation to Maintain Remission of Mild to Moderate Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00744016 |
Completed |
Bausch Health Americas, Inc. |
2007-05-31 |
| NCT00737789 |
Mesalazine 4g Once Daily Versus 4g in Two Divided Doses in Active Ulcerative Colitis. |
https://ClinicalTrials.gov/show/NCT00737789 |
Completed |
Ferring Pharmaceuticals |
2010-06-30 |
| NCT00729872 |
A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of AG011 in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00729872 |
Completed |
ActoGeniX N.V. |
2009-09-30 |
| NCT00727324 |
Safety/Efficacy Study of Bovine Intestinal Alkaline Phosphatase in Patients With Moderate to Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00727324 |
Completed |
AM-Pharma |
2006-11-30 |
| NCT00718094 |
Pilot Study of Green Tea Extract (Polyphenon E®)in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00718094 |
Completed |
University of Louisville |
2011-10-31 |
| NCT00713310 |
Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00713310 |
Completed |
Warner Chilcott |
2011-03-31 |
| NCT00708656 |
The Colitis Once Daily Asacol Study |
https://ClinicalTrials.gov/show/NCT00708656 |
Completed |
Cardiff and Vale University Health Board |
2010-07-31 |
| NCT00679432 |
(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMXâ„¢) 6 mg and 9 mg in Patients With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00679432 |
Completed |
Bausch Health Americas, Inc. |
2010-05-31 |
| NCT00679380 |
(CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMXâ„¢) 6 mg and 9 mg in Patients With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00679380 |
Completed |
Bausch Health Americas, Inc. |
2010-02-28 |
| NCT00679003 |
Managing Inflammatory Bowel Disease |
https://ClinicalTrials.gov/show/NCT00679003 |
Completed |
University of Washington |
2014-03-31 |
| NCT00659802 |
Phase II Study of HMPL-004 in Patients With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00659802 |
Completed |
Hutchison Medipharma Limited |
2009-10-31 |
| NCT02065557 |
Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT02065557 |
Completed |
AbbVie |
2020-02-07 |
| NCT00656890 |
A Study of MDX-1100 in Subjects With Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00656890 |
Completed |
Bristol-Myers Squibb |
2009-09-30 |
| NCT00643071 |
Tacrolimus (FK506) P-III, Open-label Study in Refractory Ulcerative Colitis Patients |
https://ClinicalTrials.gov/show/NCT00643071 |
Completed |
Astellas Pharma Inc |
2008-05-31 |
| NCT00620126 |
The Home Telemanagement (UC HAT) Trial for Patients With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00620126 |
Completed |
University of Maryland, Baltimore |
2010-02-28 |
| NCT00619489 |
Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn’s Disease |
https://ClinicalTrials.gov/show/NCT00619489 |
Completed |
Millennium Pharmaceuticals, Inc. |
2010-03-31 |
| NCT00616434 |
A Phase 2 Study of Interferon Beta-1a (Avonex®) in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00616434 |
Completed |
Biogen |
2010-03-31 |
| NCT00603733 |
Canadian Active & Maintenance Modified Pentasa Study |
https://ClinicalTrials.gov/show/NCT00603733 |
Completed |
Ferring Pharmaceuticals |
2011-05-31 |
| NCT00586599 |
Levels of the Stat4 Alpha and Stat4 Beta Isoforms in PBMCs From Patients With Crohn’s Disease and Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00586599 |
Completed |
Indiana University |
2014-06-30 |
| NCT00586352 |
Protein Metabolism in Newly Diagnosed Pediatric Inflammatory Bowel Disease |
https://ClinicalTrials.gov/show/NCT00586352 |
Completed |
Indiana University |
2011-11-30 |
| NCT00577473 |
Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I) |
https://ClinicalTrials.gov/show/NCT00577473 |
Completed |
Warner Chilcott |
2003-02-28 |
| NCT00573794 |
Long-term Open-label Safety and Efficacy Study of Adalimumab in Subjects With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00573794 |
Completed |
AbbVie |
2016-12-31 |
| NCT00572585 |
Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00572585 |
Completed |
Novartis |
2012-04-30 |
| NCT00568256 |
Mind/Body Medicine and IBD Flare-Up |
https://ClinicalTrials.gov/show/NCT00568256 |
Completed |
Rush University Medical Center |
2011-01-31 |
| NCT00548574 |
Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to Asacol 0.8g Three Times Daily in Subjects With Acute, Mild to Moderate Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00548574 |
Completed |
Shire |
NA |
| NCT00545389 |
Phase II Dose-Ranging Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476 |
https://ClinicalTrials.gov/show/NCT00545389 |
Completed |
Shire |
NA |
| NCT00542152 |
Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00542152 |
Completed |
Groupe d’Etude Therapeutique des Affections Inflammatoires Digestives |
2007-06-30 |
| NCT00521950 |
Cost-effectiveness of TPMT Pharmacogenetics |
https://ClinicalTrials.gov/show/NCT00521950 |
Completed |
Radboud University |
2011-12-31 |
| NCT00533078 |
Lipid Use, Nutrition, and Colitis in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00533078 |
Completed |
University Hospital Inselspital, Berne |
2009-12-31 |
| NCT00505778 |
A Comparison of Once a Day Dose Compared to 2 Doses/Day |
https://ClinicalTrials.gov/show/NCT00505778 |
Completed |
Warner Chilcott |
2009-07-31 |
| NCT00503243 |
Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00503243 |
Completed |
Shire |
NA |
| NCT00498589 |
Comparison of Methotrexate vs Placebo in Corticosteroid-dependent Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00498589 |
Completed |
Centre Hospitalier Universitaire de Besancon |
2014-02-28 |
| NCT00490048 |
Assessment of Pulmonary Involvement inUlcerative Colitis by Induced Sputum |
https://ClinicalTrials.gov/show/NCT00490048 |
Completed |
Hillel Yaffe Medical Center |
NA |
| NCT00488631 |
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00488631 |
Completed |
Janssen Research & Development, LLC |
2011-10-31 |
| NCT00486031 |
Open-Label, Long-term Balsalziade Disodium Tablet Ulcerative Colitis Study |
https://ClinicalTrials.gov/show/NCT00486031 |
Completed |
Bausch Health Americas, Inc. |
2008-04-30 |
| NCT00463151 |
An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00463151 |
Completed |
Otsuka Pharmaceutical Co., Ltd. |
2009-02-28 |
| NCT00449722 |
OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00449722 |
Completed |
Dr. Falk Pharma GmbH |
NA |
| NCT00446849 |
Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC) |
https://ClinicalTrials.gov/show/NCT00446849 |
Completed |
Shire |
2009-07-31 |
| NCT00430898 |
Basiliximab in Moderate to Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00430898 |
Completed |
Cerimon Pharmaceuticals |
2008-09-30 |
| NCT00421642 |
Open-Label Adalimumab for Ulcerative Colitis Patients |
https://ClinicalTrials.gov/show/NCT00421642 |
Completed |
Mayo Clinic |
2008-04-30 |
| NCT00417872 |
Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis |
https://ClinicalTrials.gov/show/NCT00417872 |
Completed |
Romark Laboratories L.C. |
NA |
| NCT00410410 |
A Study of Abatacept in Patients With Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00410410 |
Completed |
Bristol-Myers Squibb |
2009-06-30 |
| NCT00409396 |
A Study to Determine Whether Urinary PGE-M Levels Correlate With Ulcerative Colitis Disease |
https://ClinicalTrials.gov/show/NCT00409396 |
Completed |
Vanderbilt University |
2007-11-30 |
| NCT00408629 |
Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00408629 |
Completed |
Abbott |
2010-03-31 |
| NCT00408174 |
Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00408174 |
Completed |
Bausch Health Americas, Inc. |
2007-07-31 |
| NCT00385736 |
Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00385736 |
Completed |
Abbott |
2009-04-30 |
| NCT00382304 |
A Study of the Absorption of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea |
https://ClinicalTrials.gov/show/NCT00382304 |
Completed |
Sanofi |
NA |
| NCT00374725 |
Treatment of Ulcerative Colitis With a Combination of Lactobacillus Rhamnosus and Lactobacillus Acidophilus. |
https://ClinicalTrials.gov/show/NCT00374725 |
Completed |
Odense University Hospital |
NA |
| NCT00352404 |
Chromoscopic Guided Endomicroscpy to Diagnose Colitis Associated Dysplasia |
https://ClinicalTrials.gov/show/NCT00352404 |
Completed |
Johannes Gutenberg University Mainz |
NA |
| NCT00350415 |
A Double Blind Study for the Treatment of Acute Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00350415 |
Completed |
Warner Chilcott |
2007-05-31 |
| NCT00347048 |
Tacrolimus (FK506) Study in Moderate to Severe Refractory Ulcerative Colitis Patients |
https://ClinicalTrials.gov/show/NCT00347048 |
Completed |
Astellas Pharma Inc |
2008-04-30 |
| NCT00343850 |
Once Daily Versus Conventional Dosing of Asacol in the Maintenance of Quiescent Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00343850 |
Completed |
University of Chicago |
2007-03-31 |
| NCT00326209 |
Long-Term Safety and Tolerability of Mesalamine Pellets in Participants With Ulcerative Colitis in Remission |
https://ClinicalTrials.gov/show/NCT00326209 |
Completed |
Bausch Health Americas, Inc. |
2008-05-05 |
| NCT00304356 |
Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection |
https://ClinicalTrials.gov/show/NCT00304356 |
Completed |
VA Medical Center, Houston |
2007-01-31 |
| NCT00303381 |
Safety and Efficacy of Interferon-Beta-1a (Rebif®) for Treating Subjects With Acute Symptoms of Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00303381 |
Completed |
EMD Serono |
2003-01-31 |
| NCT00299013 |
Study of COLAL-PRED® in the Treatment of Moderate Acute Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00299013 |
Completed |
Alizyme |
2008-04-30 |
| NCT00295282 |
A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00295282 |
Completed |
Bristol-Myers Squibb |
2008-01-31 |
| NCT00269438 |
New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00269438 |
Completed |
Bausch Health Americas, Inc. |
2007-03-31 |
| NCT00267306 |
Ulcerative Colitis Study: Study of Visilizumab in Patients With Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00267306 |
Completed |
Facet Biotech |
2006-12-31 |
| NCT00261118 |
Rituximab in Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00261118 |
Completed |
Royal Liverpool University Hospital |
2009-08-31 |
| NCT00259558 |
Dose Finding Study for Retarded Phosphatidylcholine in Pancolitis |
https://ClinicalTrials.gov/show/NCT00259558 |
Completed |
Heidelberg University |
NA |
| NCT00259545 |
Retarded Phosphatidylcholine in Steroid-Dependent Chronic Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00259545 |
Completed |
Heidelberg University |
NA |
| NCT00232258 |
Nolpitantium Besylate In Patients With Ulcerative Colitis a Double-Blind, Placebo Controlled Efficacy and Safety Study |
https://ClinicalTrials.gov/show/NCT00232258 |
Completed |
Sanofi |
2006-09-30 |
| NCT00219414 |
Study for the Treatment of Ulcerative Colitis With Adacolumn (Companion to US Study 512-04-205) |
https://ClinicalTrials.gov/show/NCT00219414 |
Completed |
Otsuka Frankfurt Research Institute GmbH |
NA |
| NCT00209300 |
Pentasa Once Daily in Ulcerative Colitis for Maintenance of Remission |
https://ClinicalTrials.gov/show/NCT00209300 |
Completed |
Ferring Pharmaceuticals |
2007-05-31 |
| NCT00194818 |
Asacol Dosing Study for Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00194818 |
Completed |
University of Washington |
2007-08-31 |
| NCT00180076 |
Budesonide for Maintenance Treatment of Collagenous Colitis |
https://ClinicalTrials.gov/show/NCT00180076 |
Completed |
Technische Universität Dresden |
2007-03-31 |
| NCT00180050 |
Budesonide Treatment for Lymphocytic Colitis |
https://ClinicalTrials.gov/show/NCT00180050 |
Completed |
Technische Universität Dresden |
2006-08-31 |
| NCT00167882 |
The Influence of 5–Aminosalicylates on Thiopurine Metabolite Levels |
https://ClinicalTrials.gov/show/NCT00167882 |
Completed |
VU University Medical Center |
NA |
| NCT00151944 |
Safety and Tolerability of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis. |
https://ClinicalTrials.gov/show/NCT00151944 |
Completed |
Shire |
NA |
| NCT00151892 |
Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00151892 |
Completed |
Shire |
2009-09-30 |
| NCT00145808 |
Wireless Capsule Endoscopy in Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00145808 |
Completed |
University of Chicago |
2007-06-30 |
| NCT00145015 |
FishGastro Study: Fish Consumption and Gastro-Intestinal Health |
https://ClinicalTrials.gov/show/NCT00145015 |
Completed |
Quadram Institute Bioscience |
NA |
| NCT00798642 |
Ulcerative Colitis Relapse Prevention Trial, Hypnosis |
https://ClinicalTrials.gov/show/NCT00798642 |
Completed |
Northwestern University |
2011-11-30 |
| NCT00106509 |
A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea |
https://ClinicalTrials.gov/show/NCT00106509 |
Completed |
Sanofi |
NA |
| NCT00102193 |
Study for the Treatment of Ulcerative Colitis With Adacolumn |
https://ClinicalTrials.gov/show/NCT00102193 |
Completed |
Otsuka America Pharmaceutical |
2006-07-31 |
| NCT00096655 |
A Safety and Efficacy Study for Infliximab (Remicade) in Patients With Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00096655 |
Completed |
Centocor, Inc. |
NA |
| NCT00092508 |
CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission |
https://ClinicalTrials.gov/show/NCT00092508 |
Completed |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
NA |
| NCT00073047 |
Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00073047 |
Completed |
Facet Biotech |
NA |
| NCT00073021 |
Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00073021 |
Completed |
Warner Chilcott |
2003-09-30 |
| NCT00072943 |
A Humanized Anti-Interferon-γ Monoclonal Antibody (HuZAF) for Moderate to Severe Crohn’s Disease |
https://ClinicalTrials.gov/show/NCT00072943 |
Completed |
Facet Biotech |
2004-04-30 |
| NCT00065065 |
A Trial of Rosiglitazone for Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00065065 |
Completed |
University of Pennsylvania |
2008-01-31 |
| NCT00064454 |
FACTS II: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00064454 |
Completed |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2006-07-31 |
| NCT00064441 |
FACTS I: A Study to Test the Safety and Effectiveness of a New Medication on the Treatment of Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00064441 |
Completed |
Otsuka Pharmaceutical Development & Commercialization, Inc. |
2006-05-31 |
| NCT00063830 |
ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis. |
https://ClinicalTrials.gov/show/NCT00063830 |
Completed |
Ionis Pharmaceuticals, Inc. |
NA |
| NCT00063414 |
ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00063414 |
Completed |
Ionis Pharmaceuticals, Inc. |
NA |
| NCT00048347 |
Interferon-beta1a (AVONEX) Treatment of Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00048347 |
Completed |
National Institutes of Health Clinical Center (CC) |
2008-06-30 |
| NCT00036439 |
A Safety and Efficacy Study for Infliximab (Remicade) in Patients With Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00036439 |
Completed |
Centocor, Inc. |
NA |
| NCT00034294 |
A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea |
https://ClinicalTrials.gov/show/NCT00034294 |
Completed |
Sanofi |
NA |
| NCT00033943 |
Safety and Efficacy of OP2000 (Deligoparin) in the Treatment of Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00033943 |
Completed |
Incara Pharmaceuticals |
NA |
| NCT00032305 |
Research Study in Patients With Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00032305 |
Completed |
Facet Biotech |
2005-11-30 |
| NCT00676832 |
Study of COLAL-PRED to Treat Moderate to Severe Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00676832 |
Completed |
Prometheus Laboratories |
2009-10-31 |
| NCT00652145 |
Dose Escalation and Remission (DEAR) |
https://ClinicalTrials.gov/show/NCT00652145 |
Completed |
University of Pennsylvania |
2013-01-31 |
| NCT00628433 |
Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00628433 |
Completed |
Harbor Therapeutics |
2009-05-31 |
| NCT00002273 |
A Study of Ganciclovir in the Treatment of Cytomegalovirus of the Large Intestine in Patients With AIDS |
https://ClinicalTrials.gov/show/NCT00002273 |
Completed |
NIH AIDS Clinical Trials Information Service |
NA |
| NCT00000768 |
A Randomized Comparative Pharmacokinetic Study of Oral Ganciclovir After Treatment With Intravenous Ganciclovir for Cytomegalovirus Gastrointestinal Disease in AIDS Patients |
https://ClinicalTrials.gov/show/NCT00000768 |
Completed |
National Institute of Allergy and Infectious Diseases (NIAID) |
NA |
| NCT00720538 |
Thalidomide in Pediatric Inflammatory Bowel Diseases. |
https://ClinicalTrials.gov/show/NCT00720538 |
Completed |
IRCCS Burlo Garofolo |
2011-09-30 |
| NCT00487539 |
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00487539 |
Completed |
Janssen Research & Development, LLC |
2010-10-31 |
| NCT00366925 |
CESA 5.10 Investigation to Compare the Efficacy and Safety of the Adacolumn® Apheresis Device in Patients With Active Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00366925 |
Completed |
Otsuka Frankfurt Research Institute GmbH |
2008-02-29 |
| NCT00355602 |
Antibiotics for the Treatment of Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00355602 |
Completed |
University of Dundee |
2008-12-31 |
| NCT00004810 |
Phase II Placebo-Controlled Study of 4-Aminosalicylic Acid for Ulcerative Colitis |
https://ClinicalTrials.gov/show/NCT00004810 |
Completed |
Office of Rare Diseases (ORD) |
NA |